FDA approves Opdivo Qvantig, a new subcutaneous immunotherapy option for cancer treatment

In a significant advancement for oncology care, the U.S. Food and Drug Administration (FDA) has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous use. This ... Read More